ABEC , a global leader in biotechnology manufacturing engineering solutions and services, introduced its Advanced Therapy Bioreactor (ATB™), a revolutionary platform set to transform cell expansion for advanced therapy medicinal products (ATMPs). Designed to overcome the limitations of currently available systems, the ATB™ offers unprecedented process control and scalability from benchtop to commercial scale.
ATB™ redefines cell culture by mimicking the human circulatory system. Its proprietary hollow fiber membrane networks enable localized nutrient delivery and waste removal, ensuring optimal conditions for each cell. Unlike traditional systems that rely on bubbles and mechanical agitation, ATB’s oscillation-based mixing and diffusion-based gas and nutrient/waste transfer maintain an optimal cell growth environment for sensitive cell lines. The bioreactor and process flow paths are disposable, and the system operation is closed and fully automated.
Also Read: Aviceda Therapeutics Names Dr. Jeffrey Nau as CEO
Designed for seamless scalability, ATB™ also maintains a constant ratio of hollow fiber surface area to bioreactor volume at any scale (0.2 L to 10 L), maintaining consistent cell culture conditions from early development to clinical and commercial production. In extensive testing, ATB™ has demonstrated high density and viability for primary T cells and CD34+ stem cells, as well as HEK293 and CHO cell lines.
“The introduction of ATB™ marks another important milestone in ABEC’s 50-year history of bioprocess innovation,” said Scott Pickering, CEO of ABEC. “Like our other recombinant protein manufacturing solutions, ATB™ promises to address the toughest challenges in advanced therapeutics manufacturing and accelerate our partners’ time to clinic and time to market.”
Source: Businesswire